Skip to main content
Have a personal or library account? Click to login
Transcatheter Left Atrial Appendage Closure Cover
Open Access
|May 2023

References

  1. Korsholm K, Damgaard D, Valentin JB, et al. Left atrial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial fibrillation: rationale and design of the multicenter randomized occlusion-AF trial. Am Heart J. 2022 Jan;243:28-38. doi: 10.1016/j.ahj.2021.08.020
  2. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001 May 10;344(19):1411-20. doi: 10.1056/NEJM200105103441901
  3. Shirani J, Alaeddini J. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography. Cardiovasc Pathol. 2000 Mar-Apr;9(2):95-101. doi: 10.1016/s1054-8807(00)00030-2
  4. Collado FM, von Buchwald CM, Anderson CK, et al. Left atrial appendage occlusion for stroke prevention in nonvalvular atrial fibrillation. J Am Heart Assoc. 2021 Nov 2;10(21):e022274. doi: 10.1161/JAHA.121.022274
  5. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019 Jul 9;74(1):104-132. doi: 10.1016/j.jacc.2019.01.011
  6. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016 Nov;18(11):1609-1678. doi: 10.1093/europace/euw295
  7. CMS.gov [Internet]. Centers for Medicare & Medicaid Services. Baltimore, MD: U.S. Centers for Medicare & Medicaid Services; c2023. Percutaneous Left Atrial Appendage (LAA) Closure Therapy; 2016 [cited 2023 May 2]. Available from: https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=281
  8. BostonScientific.com [Internet]. Marlborough, MA: Boston Scientific; c2023. Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Antiplatelet Therapy as Post-Procedural Medication Option; 2022 Sep 6 [cited 2023 May 2]. Available from: https://news.bostonscientific.com/2022-09-06-Boston-Scientific-Receives-FDA-Approval-for-Expanded-Labeling-of-WATCHMAN-FLX-TM-LAAC-Device-for-Dual-Anti-Platelet-Therapy-as-Post-Procedural-Medication-Option
  9. De Backer O, Arnous S, Ihlemann N, et al. Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update. Open Heart. 2014 Jun 6;1(1):e000020. doi: 10.1136/openhrt-2013-000020
  10. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. CHAMPION-AF Clinical Trial (CHAMPION-AF); 2023 Apr 3 [cited 2023 Apr 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT04394546
  11. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. Amplatzer Amulet LAAO vs. NOAC (CATALYST); 2023 Feb 27 [cited 2023 Apr 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT04226547
  12. Daimee UA, Wang Y, Masoudi FA, et al. Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry. Circ Cardiovasc Qual Outcomes. 2022 Aug;15(8):e008418. doi: 10.1161/CIRCOUTCOMES.121.008418
  13. Huded C, Krishnaswamy A, Kapadia S. Percutaneous Left Atrial Appendage Closure: is there a Role in Valvular Atrial Fibrillation. J Atr Fibrillation. 2017 Feb 28;9(5):1524. doi: 10.4022/jafib.1524
  14. Yap J, Chen S, Stripe BR, et al. Transseptal access for left heart structural interventions in the setting of prior atrial septal defect closure. Catheter Cardiovasc Interv. 2020 Feb 15;95(3):414-419. doi: 10.1002/ccd.28548
  15. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009 Aug 15;374(9689):534-42. doi: 10.1016/S0140-6736(09)61343-X
  16. Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014 Jul 8;64(1):1-12. doi: 10.1016/j.jacc.2014.04.029
  17. Kar S, Doshi SK, Sadhu A, et al. Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial. Circulation. 2021 May 4;143(18):1754-1762. doi: 10.1161/CIRCULATIONAHA.120.050117
  18. Singh GD, Rogers JH, Saw J. Watchman FLX: Early “Real World” Experience in Search for the Perfect Closure. JACC Cardiovasc Interv. 2020 Dec 14;13(23):2742-2744. doi: 10.1016/j.jcin.2020.07.043
  19. Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. Circulation. 2021 Nov 9;144(19):1543-1552. doi: 10.1161/CIRCULATIONAHA.121.057063
  20. Srivastava MC, See VY, Dawood MY, Price MJ. A review of the LARIAT device: insights from the cumulative clinical experience. Springerplus. 2015 Sep 17;4:522. doi: 10.1186/s40064-015-1289-8
  21. Wilber D. Outcomes of adjunctive left atrial appendage ligation utilizing the Lariat compared to pulmonary vein antral isolation alone: the aMAZE trial. Paper presented at: American Heart Association 2021; 2021.
  22. Ali M, Rigopoulos AG, Mammadov M, et al. Systematic review on left atrial appendage closure with the LAmbre device in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2020 Feb 12;20(1):78. doi: 10.1186/s12872-020-01349-9
  23. Ke J, Jin L, Lin Y, et al. Combined atrial fibrillation ablation and left atrial appendage closure: Watchman vs. LAmbre devices. Front Cardiovasc Med. 2022 Nov 2;9:1011037. doi: 10.3389/fcvm.2022.1011037
  24. Cheung GS, So KC, Chan CK, et al. Comparison of three left atrial appendage occlusion devices for stroke prevention in patients with non-valvular atrial fibrillation: a single-centre seven-year experience with WATCHMAN, AMPLATZER Cardiac Plug/Amulet, LAmbre: Comparison of three LAAO devices for stroke prevention. AsiaIntervention. 2019 Feb;5(1):57-63. doi: 10.4244/AIJ-D-18-00013
  25. Chen S, Chun KR, Bordignon S, et al. Left atrial appendage occlusion using LAmbre Amulet and Watchman in atrial fibrillation. J Cardiol. 2019 Apr;73(4):299-306. doi: 10.1016/j.jjcc.2018.10.010
  26. Boersma LV. New Left Atrial Appendage Devices: Revelation or Conformal? JACC Clin Electrophysiol. 2022 Feb;8(2):208-210. doi: 10.1016/j.jacep.2022.01.014
  27. Turagam MK, Neuzil P, Hala P, Mraz T, Dukkipati SR, Reddy VY. Intracardiac Echocardiography-Guided Left Atrial Appendage Closure With a Novel Foam-Based Conformable Device: Safety and 1-Year Outcomes. JACC Clin Electrophysiol. 2022 Feb;8(2):197-207. doi: 10.1016/j.jacep.2021.10.001
  28. Sommer RJ, Kim JH, Szerlip M, et al. Conformal Left Atrial Appendage Seal Device for Left Atrial Appendage Closure: First Clinical Use. JACC Cardiovasc Interv. 2021 Nov 8;14(21):2368-2374. doi: 10.1016/j.jcin.2021.08.060
  29. Freitas-Ferraz AB, Bernier M, Vaillancourt R, et al. Safety of Transesophageal Echocardiography to Guide Structural Cardiac Interventions. J Am Coll Cardiol. 2020 Jun 30;75(25):3164-3173. doi: 10.1016/j.jacc.2020.04.069
  30. Korsholm K, Jensen JM, Nielsen-Kudsk JE. Intracardiac Echocardiography From the Left Atrium for Procedural Guidance of Transcatheter Left Atrial Appendage Occlusion. JACC Cardiovasc Interv. 2017 Nov 13;10(21):2198-2206. doi: 10.1016/j.jcin.2017.06.057
  31. Korsholm K, Samaras S, Andersen A, Jensen JM. The Watchman FLX Device: First European Experience and Feasibility of Intracardiac Echocardiography to Guide Implantation. JACC Clin Electrophysiol. 2020 Dec 14;6(13):1633-1642. doi: 10.1016/j.jacep.2020.06.028
  32. Alkhouli M, Chaker Z, Alqahtani F, Raslan S, Raybuck B. Outcomes of Routine Intracardiac Echocardiography to Guide Left Atrial Appendage Occlusion. JACC Clin Electrophysiol. 2020 Apr;6(4):393-400. doi: 10.1016/j.jacep.2019.11.014
  33. Goldsweig AM, Alkhouli M. Let It Go: Intracardiac Echocardiography Is the Future of Imaging for Left Atrial Appendage Occlusion. J Soc Cardiovasc Angio Interv. 2022 Nov;1(6). doi: 10.1016/j.jscai.2022.100518
  34. Hemam ME, Kuroki K, Schurmann PA, et al. Left atrial appendage closure with the Watchman device using intracardiac vs transesophageal echocardiography: Procedural and cost considerations. Heart Rhythm. 2019 Mar;16(3):334-342. doi: 10.1016/j.hrthm.2018.12.013
  35. Pommier T, Guenancia C, Richard C, et al. Safety and efficacy of left atrial appendage occlusion with the ACP or Watchman device guided by intracardiac echocardiography from the left atrium. Clin Cardiol. 2021 Oct;44(10):1402-1408. doi: 10.1002/clc.23696
  36. Dallan LA, Bezerra HG, Cochet A, et al. Safety, Efficacy, and Cost-Effectiveness of Same-Day Discharge for Left Atrial Appendage Occlusion. J Invasive Cardiol. 2022 Feb;34(2):E124-E131.
  37. Chew DS, Piccini JP. Postprocedural Antithrombotic Therapy Following Left Atrial Appendage Occlusion: No Longer Adrift in Uncertainty? Circ Cardiovasc Interv. 2020 Jul;13(7):e009534. doi: 10.1161/CIRCINTERVENTIONS.120.009534
  38. Freeman JV, Higgins AY, Wang Y, et al. Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2022 May 10;79(18):1785-1798. doi: 10.1016/j.jacc.2022.02.047
  39. Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017 Sep;14(9):1302-1308. doi: 10.1016/j.hrthm.2017.05.038
  40. TCTMD [Internet]. Beverly Hills, CA: Cardiovascular Research Foundation; c2023. Comparative Effectiveness of Post-procedure Medications Following Left Atrial Appendage Occlusion: A DAPT Analysis With WATCHMAN FLX; 2022 Jun 9 [cited 2023 May 2]. Available from: https://www.tctmd.com/slide/comparative-effectiveness-post-procedure-medications-following-left-atrial-appendage
  41. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (ANDES); 2022 Jul 13 [cited 2023 Apr 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT03568890
  42. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Library of Medicine; c2023. Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure (SAFE-LAAC); 2022 Jul 6 [cited 2023 Apr 19]. Available from: https://clinicaltrials.gov/ct2/show/NCT03445949
DOI: https://doi.org/10.14797/mdcvj.1215 | Journal eISSN: 1947-6108
Language: English
Page range: 67 - 77
Submitted on: Feb 6, 2023
Accepted on: Feb 28, 2023
Published on: May 16, 2023
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2023 Gordon X. Wong, Gagan D. Singh, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.